Price to Earnings (P/E)
since 2005
Paying user area
Try for free
Bristol-Myers Squibb Co. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Common-Size Balance Sheet: Assets
- Analysis of Solvency Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Price to FCFE (P/FCFE)
- Dividend Discount Model (DDM)
- Net Profit Margin since 2005
- Debt to Equity since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Bristol-Myers Squibb Co. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Bristol-Myers Squibb Co., P/E, long-term trends, calculation
| P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net earnings (loss) attributable to BMS1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 12, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 14, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 9, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 10, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 12, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 14, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 15, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 18, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2008 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 14, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Bristol-Myers Squibb Co. Annual Report.
The share price exhibits considerable variability over the periods analyzed. Starting at $22.91 in 2006, it generally increased with intermittent fluctuations, reaching peaks near $60 between 2014 and 2016. After a dip around 2018 to 2019, the price recovered and peaked at $72.25 in 2023, followed by a notable decline to $48.71 in 2024, and then a moderate recovery to $56.15 in 2025. This pattern suggests periods of growth interrupted by volatility, likely influenced by external market conditions and company performance factors.
Earnings per share (EPS) show a highly volatile pattern throughout the years. EPS began at $1.53 in 2006, with sharp fluctuations such as the surge to $6.19 in 2010, followed by declines and subsequent rebounds. Noteworthy is the negative EPS recorded in 2021 (-$4.02) and 2025 (-$4.41), indicating losses during those years. Between these, EPS experienced recovery and growth phases, reaching highs of around $3.97 in 2024. The erratic EPS trend points to inconsistent profitability and potential operational challenges or one-time charges that impacted earnings.
The price-to-earnings (P/E) ratio, calculated as the share price divided by EPS, reflects the fluctuations in both earnings and market valuation. The ratio started at 14.96 in 2006, rising sharply to values above 30 several times, and even reaching 103.55 in 2018, indicating periods when the market priced the stock very aggressively relative to earnings. The P/E ratio shows substantial increases during years of low or depressed EPS, amplifying valuation multiples. Missing P/E values for some years align with negative EPS, where P/E is not meaningful. The overall P/E trend suggests periods of high investor optimism and times when earnings dipped significantly, affecting valuation metrics.
Comparison to Competitors
Bristol-Myers Squibb Co., P/E, long-term trends, comparison to competitors
| Bristol-Myers Squibb Co. | AbbVie Inc. | Amgen Inc. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 12, 2025 | ||||||||||||
| Feb 13, 2024 | ||||||||||||
| Feb 14, 2023 | ||||||||||||
| Feb 9, 2022 | ||||||||||||
| Feb 10, 2021 | ||||||||||||
| Feb 24, 2020 | ||||||||||||
| Feb 25, 2019 | ||||||||||||
| Feb 13, 2018 | ||||||||||||
| Feb 21, 2017 | ||||||||||||
| Feb 12, 2016 | ||||||||||||
| Feb 13, 2015 | ||||||||||||
| Feb 14, 2014 | ||||||||||||
| Feb 15, 2013 | ||||||||||||
| Feb 17, 2012 | ||||||||||||
| Feb 18, 2011 | ||||||||||||
| Feb 19, 2010 | ||||||||||||
| Feb 20, 2009 | ||||||||||||
| Feb 22, 2008 | ||||||||||||
| Feb 26, 2007 | ||||||||||||
| Mar 14, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Bristol-Myers Squibb Co., P/E, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Bristol-Myers Squibb Co. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 12, 2025 | ||
| Feb 13, 2024 | ||
| Feb 14, 2023 | ||
| Feb 9, 2022 | ||
| Feb 10, 2021 | ||
| Feb 24, 2020 | ||
| Feb 25, 2019 | ||
| Feb 13, 2018 | ||
| Feb 21, 2017 | ||
| Feb 12, 2016 | ||
| Feb 13, 2015 | ||
| Feb 14, 2014 | ||
| Feb 15, 2013 | ||
| Feb 17, 2012 | ||
| Feb 18, 2011 | ||
| Feb 19, 2010 | ||
| Feb 20, 2009 | ||
| Feb 22, 2008 | ||
| Feb 26, 2007 | ||
| Mar 14, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Bristol-Myers Squibb Co., P/E, long-term trends, comparison to industry (health care)
| Bristol-Myers Squibb Co. | Health Care | |
|---|---|---|
| Feb 12, 2025 | ||
| Feb 13, 2024 | ||
| Feb 14, 2023 | ||
| Feb 9, 2022 | ||
| Feb 10, 2021 | ||
| Feb 24, 2020 | ||
| Feb 25, 2019 | ||
| Feb 13, 2018 | ||
| Feb 21, 2017 | ||
| Feb 12, 2016 | ||
| Feb 13, 2015 | ||
| Feb 14, 2014 | ||
| Feb 15, 2013 | ||
| Feb 17, 2012 | ||
| Feb 18, 2011 | ||
| Feb 19, 2010 | ||
| Feb 20, 2009 | ||
| Feb 22, 2008 | ||
| Feb 26, 2007 | ||
| Mar 14, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).